TY - JOUR
T1 - Regression of isoproterenol-induced cardiac hypertrophy by Na+/H+ exchanger inhibition
AU - Ennis, Irene L.
AU - Escudero, Eduardo M.
AU - Console, Gloria M.
AU - Camihort, Gisela
AU - Dumm, César Gomez
AU - Seidler, Randolph W.
AU - Camilión de Hurtado, María C.
AU - Cingolani, Horacio E.
PY - 2003/6/1
Y1 - 2003/6/1
N2 - Cardiac hypertrophy is often associated with an increased sympathetic drive, and both in vitro and in vivo studies have demonstrated the development of cardiomyocyte hypertrophy in response to either α- or β-adrenergic stimulation. Because an association between the Na+/H+ exchanger and cellular growth has been proposed, this study aimed to analyze the possible role of the antiporter in isoproterenol-induced cardiac hypertrophy. Isoproterenol alone (5 mg/kg IP once daily) or combined with a selective inhibitor of the Na+/H+ exchanger activity (3 mg · kg-1 · d-1 BIIB723) was given to male Wistar rats for 30 days. Sex- and age-matched rats that received 0.9% saline IP daily served as controls. Echocardiographic follow-up showed a 33% increase in left ventricular mass in the isoproterenol-treated group, whereas it did not increase in the isoproterenol+BIIB723-treated group. Heart weight-to-body weight ratio at necropsy was 2.44 ± 0.11 in controls and increased to 3.35 ± 0.10 (P < 0.05) with isoproterenol, an effect that was markedly attenuated by BIIB723 (2.82 ± 0.07). Intense cardiomyocyte enlargement and severe subendocardial fibrosis were found in isoproterenol-treated rats, and both effects were attenuated by BIIB723. Myocardial Na+/H+ exchanger activity and protein expression significantly increased in isoproterenol-treated rats compared with the control group (1.45 ± 0.11 vs 0.91 ± 0.05 arbitrary units, P < 0.05). This effect was significantly reduced by BIIB723 (1.17 ± 0.02, P < 0.05). In conclusion, our results show that Na+/H+ exchanger inhibition prevented the development of isoproterenol-induced hypertrophy and fibrosis, providing strong evidence in favor of a key role played by the antiporter in this model of cardiac hypertrophy.
AB - Cardiac hypertrophy is often associated with an increased sympathetic drive, and both in vitro and in vivo studies have demonstrated the development of cardiomyocyte hypertrophy in response to either α- or β-adrenergic stimulation. Because an association between the Na+/H+ exchanger and cellular growth has been proposed, this study aimed to analyze the possible role of the antiporter in isoproterenol-induced cardiac hypertrophy. Isoproterenol alone (5 mg/kg IP once daily) or combined with a selective inhibitor of the Na+/H+ exchanger activity (3 mg · kg-1 · d-1 BIIB723) was given to male Wistar rats for 30 days. Sex- and age-matched rats that received 0.9% saline IP daily served as controls. Echocardiographic follow-up showed a 33% increase in left ventricular mass in the isoproterenol-treated group, whereas it did not increase in the isoproterenol+BIIB723-treated group. Heart weight-to-body weight ratio at necropsy was 2.44 ± 0.11 in controls and increased to 3.35 ± 0.10 (P < 0.05) with isoproterenol, an effect that was markedly attenuated by BIIB723 (2.82 ± 0.07). Intense cardiomyocyte enlargement and severe subendocardial fibrosis were found in isoproterenol-treated rats, and both effects were attenuated by BIIB723. Myocardial Na+/H+ exchanger activity and protein expression significantly increased in isoproterenol-treated rats compared with the control group (1.45 ± 0.11 vs 0.91 ± 0.05 arbitrary units, P < 0.05). This effect was significantly reduced by BIIB723 (1.17 ± 0.02, P < 0.05). In conclusion, our results show that Na+/H+ exchanger inhibition prevented the development of isoproterenol-induced hypertrophy and fibrosis, providing strong evidence in favor of a key role played by the antiporter in this model of cardiac hypertrophy.
KW - Adrenergic receptor agonists
KW - Antiporters
KW - Fibrosis
KW - Hypertrophy, cardiac
KW - Signal transduction
UR - http://www.scopus.com/inward/record.url?scp=0038795603&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038795603&partnerID=8YFLogxK
U2 - 10.1161/01.HYP.0000071180.12012.6E
DO - 10.1161/01.HYP.0000071180.12012.6E
M3 - Article
C2 - 12732584
AN - SCOPUS:0038795603
SN - 0194-911X
VL - 41
SP - 1324
EP - 1329
JO - Hypertension
JF - Hypertension
IS - 6
ER -